Pancreatic cancer
Drug research and approvals for pancreatic cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 886 studies of pancreatic cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 24 drug trials for it since 2013, and FDA has 6 approved and 226 open orphan designations naming it.
- Recruiting worldwide: 886
- Trials authorized in Canada: 24
- FDA orphan approvals: 6
- EU medicines: 0
- A Phase I/II Open-label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Rejuvenated…NCT07948070 · Phase 1 / Phase 2 · Tianjin Medical University Cancer Institute and Hospital · starts Jun 2, 2026
- The imPAct of nutritioN on the Outcome of pancrEATic Surgery; Food for Thought.NCT07940309 · Not reported · Maastricht University Medical Center · starts Oct 1, 2026
- Liver Metastasis in Pancreatic Ductal Adenocarcinoma: Regulatory Mechanisms and Clinical SignificanceNCT07933952 · Not reported · Nanjing Medical University · starts Oct 22, 2026
- Artificial Intelligence-Assisted 4D Dynamic Long-Axial PET Imaging for the Detection of Early Pancreatic Cancer LesionsNCT07925125 · Not reported · Ruijin Hospital · starts Nov 15, 2024
- A KRAS Inhibitor in Participants With Advanced Solid TumorsNCT07912593 · Phase 1 / Phase 2 · Ensem Therapeutics · starts Oct 22, 2026
- The Use of Contrast Enhanced Ultrasound (CEUS) In Post-Surgical Pancreatic Cancer Patients to Evaluate Local Disease…NCT07910383 · Not applicable · Thomas Jefferson University · starts Jul 29, 2026
- Development and Utilization of an Integrated Clinical Genomic DatabaseNCT07911267 · Not reported · Samsung Medical Center · starts Dec 6, 2024
- A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.NCT07903415 · Phase 1 · Pfizer · starts Nov 5, 2026
- Implementation of a Pain Management Plan in Major Open Abdominal Surgeries.NCT07901582 · Not applicable · National and Kapodistrian University of Athens · starts Nov 22, 2025
Approved 8
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- PaclitaxelTubulin inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- ErlotinibEpidermal growth factor receptor erbB1 inhibitor
- OlaparibPARP 1, 2 and 3 inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- DiazoxideIslet cell adenoma · Potassium channel, inwardly rectifying, subfamily J, member 11 opener
- ZenocutuzumabErbB-2/ErbB-3 heterodimer inhibitor
Phase 3 12 of 56
- FluorouracilThymidylate synthase inhibitor
- OxaliplatinDNA inhibitor
- Leucovorin
- CapecitabineThymidylate synthase inhibitor
- CisplatinDNA inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
- CetuximabEpidermal growth factor receptor erbB1 inhibitor
- GimeracilDihydropyrimidine dehydrogenase inhibitor
- TegafurRNA inhibitor
- Oteracil
- MitomycinDNA inhibitor
- NimotuzumabEpidermal growth factor receptor erbB1 inhibitor
Phase 2 12 of 218
- DocetaxelTubulin inhibitor
- PembrolizumabProgrammed cell death protein 1 inhibitor
- NivolumabProgrammed cell death protein 1 inhibitor
- CyclophosphamideDNA inhibitor
- DurvalumabProgrammed cell death 1 ligand 1 inhibitor
- IpilimumabCytotoxic T-lymphocyte protein 4 inhibitor
- HydroxychloroquineFerriprotoporphyrin IX inhibitor
- AvelumabProgrammed cell death 1 ligand 1 other
- PanitumumabEpidermal growth factor receptor erbB1 inhibitor
- ParicalcitolVitamin D receptor agonist
- Interferon alfa
- Nogapendekin alfa
Phase 1 or earlier 12 of 153
- Clivatuzumab tetraxetanMucin-5AC binding agent
- LMB-9Lewis Y antigen binding agent
- Hiltonol
- SonidegibSmoothened homolog inhibitor
- VorinostatHistone deacetylase 1 inhibitor
- NelfinavirHuman immunodeficiency virus type 1 protease inhibitor
- Omega-3-ACID ethyl esters
- PalbociclibPancreatic ductal cancer · CDK6/cyclin D1 inhibitor
- UlixertinibMAP kinase ERK1 inhibitor
- GanitumabInsulin-like growth factor I receptor antagonist
- Talimogene laherparepvecMelanoma cell disrupting agent
- TalazoparibPoly [ADP-ribose] polymerase 2 inhibitor
How its trials ended
2,776 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 638 whose ending is known, 21% met their primary endpoint, 12% missed it and 67% stopped early.
- Completed, result not reported90833%
- Ongoing82530%
- Status unknown40515%
- Stopped: other or unclear2077%
- Met its primary endpoint1335%
- Stopped: enrollment or feasibility1044%
- Missed its primary endpoint773%
- Stopped: sponsor or business decision522%
- Stopped: lack of efficacy351%
- Stopped: funding211%
- Stopped: safety9<1%
| Oct 29, 2026 | A phase 2, open-label, master protocol study to evaluate safety and efficacy of treatment combinations with telisotuzumab adizutecan in subjects with…Telisotuzumab adizutecan (ABBV-400) / Gemcitabine | AbbVie | Pending |
| Aug 14, 2024 | Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177lu]LU-NNS309 in patients with…[177LU]LU-NNS309 (FXX489) / [68GA]GA-NNS309 (FFG233) | Novartis Pharmaceuticals | Ongoing |
| Jul 15, 2024 | Microbubble-assisted MRI-guided focused ultrasound with chemotherapy in locally advanced unresectable pancreatic cancer (focus-lapc)Oxaliplatin | Arrayus Technologies Inc. | Pending |
| Mar 26, 2024 | A phase 1b study evaluating the safety, tolerability, pharmacokinetics, and efficacy of amg 193 in combination with other therapies in subjects with advanced…Amg 193 | Amgen | Pending |
| May 31, 2023 | A phase 1 study of olaparib in combination with durvalumab (MEDI4736) and concurrent radiation therapy following first-line chemotherapy in locally advanced…Olaparib / Durvalumab | University Health Network | Ongoing |
| Aug 19, 2021 | Greco-2: a randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with GC4711 in the treatment of unresectable or borderline…Avasopasem (GC4711) | Galera Therapeutics | Ongoing |
| Jun 3, 2020 | A phase 2 study of saltikva (attenuated salmonella typhimurium containing the human gene for interleukin-2) in patients with unresectable pancreatic cancerSaltikva (attenuated salmonella typhimurium containing the human gene for… | Salspera Llp | Ongoing |
| Mar 23, 2020 | Feasibility study of hypoxia and re-oxygenation imaging in pancreatic cancer using positron emission tomography (PET) with [18f] fluoroazomycin-arabinoside…[F-18]-FAZA | Princess Margaret Cancer Centre | Ongoing |
| Feb 28, 2020 | A phase II/III randomized, open-label clinical study of napabucasin in combination with weekly paclitaxel and low-dose gemcitabine in patients with metastatic…Napabucasin (GB201) / Paclitaxel | 1Globe Health Institute | Ongoing |
| Jan 13, 2020 | "a phase 3, randomized, double-blindstudy of pamrevlumabor placeboin combination with gemcitabine plus nab-paclitaxelas neoadjuvant treatment in patients with…Pamrevlumab (FG-3019) | Fibrogen Incorporated | Ongoing |
| Aug 26, 2026 | RasonqueTreatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not… | Revolution Medicines, Inc. | Approved |
| Dec 4, 2024 | BizengriTreatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with… | Partner Therapeutics, Inc. | Approved |
| Feb 13, 2024 | OnivydeIn combination with oxaliplatin, fluorouracil and leucovorin for the first-line treatment of adult patients with metastatic pancreatic… | Ipsen Biopharmaceuticals, Inc. | Approved |
| Dec 27, 2019 | LynparzaLynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic… | AstraZeneca Pharmaceuticals LP | Approved |
| Oct 22, 2015 | Irinotecan liposome injectionFor use in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas that… | Ipsen Biopharmaceuticals, Inc. | Approved |
| Sep 6, 2013 | AbraxaneTreatment of metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine. | Abraxis BioScience, LLC | Approved |
| Oct 5, 2026 | 225Ac chelated with SKL35500 (consists of a ligand, a…Treatment of pancreatic cancer | SK Life Science, Inc. | Designated |
| Oct 5, 2026 | OlomorasibTreatment of pancreatic cancer | Eli Lilly and Company | Designated |
| Sep 21, 2026 | Nuzefatide pevedotinTreatment of pancreatic cancer | BicycleTx Ltd | Designated |
| Sep 15, 2026 | ZoldonrasibTreatment of pancreatic cancer | Revolution Medicines, Inc. | Designated |
| Sep 14, 2026 | Antibody drug conjugate composed of recombinant humanized…Treatment of pancreatic cancer | ArriVent BioPharma Inc. | Designated |
| Sep 11, 2026 | Anti-CDH17 monoclonal antibody-DNA topoisomerase I…Treatment of pancreatic cancer | Wealth Venture US Inc | Designated |
| Aug 27, 2026 | Flavopereirine-derived beta-carboline alkaloid DNA…Treatment of pancreatic cancer | Mirkine Pharma, Incorporated | Designated |
| Jul 21, 2026 | Anti-tissue factor monoclonal antibody conjugated to…Treatment of pancreatic cancer | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Designated |
| Jul 9, 2026 | MTA-cooperative PRMT5 inhibitorTreatment of pancreatic cancer | BeOne Medicines USA, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA